newsfilter
← Latest News
Business Wire·

Boundless Bio Announces Pricing of Initial Public Offering

Boundless Bio, Inc. (NASDAQ:BOLD), a clinical stage oncology company interrogating extrachromosomal DNA (ecDNA) biology to deliver transformative therapies to patients with previously intractable oncogene amplified